Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability. The company also ...

Labcorp Holdings Inc. LH, or Labcorp, is slated to report its fourth-quarter 2025 results on Feb. 17, before the market opens. The renowned laboratory service provider reported adjusted earnings of $4 ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors rule out the disease in people 55 and older with symptoms of cognitive ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Labcorp is expanding its ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...

Labcorp Holdings Inc. LH, or Labcorp, is slated to report its fourth-quarter 2025 results on Feb. 17, before the market opens. The renowned laboratory service provider reported adjusted earnings of $4 ...

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well ...

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...